标题
CDK4/6 Inhibitors in Melanoma: A Comprehensive Review
作者
关键词
-
出版物
Cells
Volume 10, Issue 6, Pages 1334
出版商
MDPI AG
发表日期
2021-05-28
DOI
10.3390/cells10061334
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Meta-Analysis and Systematic Review of the Genomics of Mucosal Melanoma
- (2021) Natasa Broit et al. MOLECULAR CANCER RESEARCH
- The Molecular Landscape of Primary Acral Melanoma: A Multicenter Study of the Italian Melanoma Intergroup (IMI)
- (2021) Lisa Elefanti et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future
- (2020) Laura M Spring et al. LANCET
- An update on the implications of cyclin D1 in melanomas
- (2020) Lucia González‐Ruiz et al. Pigment Cell & Melanoma Research
- Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
- (2020) Lauren E. Stopfer et al. Nature Communications
- Venous thromboembolism risk in patients with hormone receptor-positive HER2-negative metastatic breast cancer treated with combined CDK 4/6 inhibitors plus endocrine therapy versus endocrine therapy alone: a systematic review and meta-analysis of randomized controlled trials
- (2020) Kyaw Zin Thein et al. BREAST CANCER RESEARCH AND TREATMENT
- Role of immune cells in the removal of deleterious senescent cells
- (2020) Abhijit Kale et al. Immunity & Ageing
- Activation of CD8+ T Cells Contributes to Antitumor Effects of CDK4/6 Inhibitors plus MEK Inhibitors
- (2020) Jessica L.F. Teh et al. Cancer Immunology Research
- Getting under the skin: The role of CDK4/6 in melanomas
- (2020) Linghong Guo et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- CDK4/6 Inhibitors in Breast Cancer Treatment: Potential Interactions with Drug, Gene, and Pathophysiological Conditions
- (2020) Rossana Roncato et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma
- (2020) Reinhard Dummer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Inhibiting CDK4/6 in Breast Cancer with Palbociclib, Ribociclib, and Abemaciclib: Similarities and Differences
- (2020) C. Louwrens Braal et al. DRUGS
- Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer
- (2020) Zhen Li et al. Frontiers in Pharmacology
- Cyclin D1 in Cancer: A Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma
- (2020) Francesca Ida Montalto et al. Cells
- MicroRNA-Mediated Suppression of the TGF-β Pathway Confers Transmissible and Reversible CDK4/6 Inhibitor Resistance
- (2019) Liam Cornell et al. Cell Reports
- Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer
- (2019) Luigi Formisano et al. Nature Communications
- Cyclin E1 Expression and Palbociclib Efficacy in Previously Treated Hormone Receptor–Positive Metastatic Breast Cancer
- (2019) Nicholas C. Turner et al. JOURNAL OF CLINICAL ONCOLOGY
- A functional landscape of resistance to MEK1/2 and CDK4/6 inhibition in NRAS mutant melanoma
- (2019) Tikvah K Hayes et al. CANCER RESEARCH
- 166PPooled safety analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2– advanced breast cancer (ABC)
- (2019) D Tripathy et al. ANNALS OF ONCOLOGY
- Palbociclib (P) in advanced acral lentiginous melanoma (ALM) with CDK4 pathway gene aberrations.
- (2019) Lili Mao et al. JOURNAL OF CLINICAL ONCOLOGY
- Phase I-II open label multicenter study of PD0332991 in BRAFV600mut metastatic melanoma patients harboring CDKN2A loss and RB1 expression and treated with vemurafenib.
- (2019) Baptiste Louveau et al. JOURNAL OF CLINICAL ONCOLOGY
- A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
- (2019) Shubham Pant et al. JOURNAL OF CLINICAL ONCOLOGY
- Third-generation CDK inhibitors: A review on the synthesis and binding modes of Palbociclib, Ribociclib and Abemaciclib
- (2019) Melania Poratti et al. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
- Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study
- (2019) Caroline Robert et al. LANCET ONCOLOGY
- Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma
- (2019) Jiayi Yu et al. CLINICAL CANCER RESEARCH
- Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- (2019) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Regulation of PRMT5–MDM4 axis is critical in the response to CDK4/6 inhibitors in melanoma
- (2019) Shatha AbuHammad et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- MDM2 antagonists overcome intrinsic resistance to CDK4/6 inhibition by inducing p21
- (2019) Anna E. Vilgelm et al. Science Translational Medicine
- SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors
- (2019) Akihiro Yoshida et al. Science Advances
- 331PA phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL)
- (2019) S Sahebjam et al. ANNALS OF ONCOLOGY
- The double dealing of cyclin D1
- (2019) Guergana Tchakarska et al. CELL CYCLE
- Abstract P5-21-15: The synergistic antitumor activity of entinostat (MS-275) in combination with palbociclib (PD 0332991) in estrogen receptor-positive and triple-negative breast cancer
- (2018) J Lee et al. CANCER RESEARCH
- Palbociclib synergizes with BRAF and MEK inhibitors in treatment naïve melanoma but not after the development of BRAF inhibitor resistance
- (2018) Claire A. Martin et al. INTERNATIONAL JOURNAL OF CANCER
- Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF -mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
- (2018) Reinhard Dummer et al. LANCET ONCOLOGY
- PDLIM7 and CDH18 regulate the turnover of MDM2 during CDK4/6 inhibitor therapy-induced senescence
- (2018) Mary E. Klein et al. ONCOGENE
- In Vivo E2F Reporting Reveals Efficacious Schedules of MEK1/2–CDK4/6 Targeting and mTOR–S6 Resistance Mechanisms
- (2018) Jessica L.F. Teh et al. Cancer Discovery
- A phase I study of LXH254 in patients (pts) with advanced solid tumors harboring MAPK pathway alterations.
- (2018) Filip Janku et al. JOURNAL OF CLINICAL ONCOLOGY
- The identification of patient-specific mutations reveals dual pathway activation in most patients with melanoma and activated receptor tyrosine kinases in BRAF/NRAS wild-type melanomas
- (2018) Silke Appenzeller et al. CANCER
- Loss of the FAT1 Tumor Suppressor Promotes Resistance to CDK4/6 Inhibitors via the Hippo Pathway
- (2018) Zhiqiang Li et al. CANCER CELL
- A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade
- (2018) Livnat Jerby-Arnon et al. CELL
- Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
- (2018) Sunilkumar Kakadia et al. OncoTargets and Therapy
- Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine
- (2017) Liang Cheng et al. MODERN PATHOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Cyclin D–CDK4 kinase destabilizes PD-L1 via cullin 3–SPOP to control cancer immune surveillance
- (2017) Jinfang Zhang et al. NATURE
- Whole-genome landscapes of major melanoma subtypes
- (2017) Nicholas K. Hayward et al. NATURE
- Oncogenic BRAF fusions in mucosal melanomas activate the MAPK pathway and are sensitive to MEK/PI3K inhibition or MEK/CDK4/6 inhibition
- (2017) H S Kim et al. ONCOGENE
- CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers
- (2017) Smruthi Vijayaraghavan et al. Nature Communications
- CDK4/6 Inhibition Augments Antitumor Immunity by Enhancing T-cell Activation
- (2017) Jiehui Deng et al. Cancer Discovery
- The APC/C E3 Ligase Complex Activator FZR1 Restricts BRAF Oncogenic Function
- (2017) Lixin Wan et al. Cancer Discovery
- 1086OPHASE IB/II STUDY OF LEE011 (CDK4/6 INHIBITOR) AND LGX818 (BRAF INHIBITOR) IN BRAF-MUTANT MELANOMA
- (2017) M. Taylor et al. ANNALS OF ONCOLOGY
- Induction of Therapeutic Senescence in Vemurafenib-Resistant Melanoma by Extended Inhibition of CDK4/6
- (2016) A. Yoshida et al. CANCER RESEARCH
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Acquired CDK6 amplification promotes breast cancer resistance to CDK4/6 inhibitors and loss of ER signaling and dependence
- (2016) C Yang et al. ONCOGENE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment
- (2015) T. VanArsdale et al. CLINICAL CANCER RESEARCH
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine
- (2014) Lawrence M. Gelbert et al. INVESTIGATIONAL NEW DRUGS
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- The Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
- (2013) K. E. Sheppard et al. CLINICAL CANCER RESEARCH
- The Cyclin-dependent Kinase Inhibitor p16INK4aPhysically Interacts with Transcription Factor Sp1 and Cyclin-dependent Kinase 4 to Transactivate MicroRNA-141 and MicroRNA-146b-5p Spontaneously and in Response to Ultraviolet Light-induced DNA Damage
- (2013) Huda H. Al-Khalaf et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Melanoma: from mutations to medicine
- (2012) H. Tsao et al. GENES & DEVELOPMENT
- Cyclin-Dependent Kinases Are Regulators and Effectors of Oscillations Driven by a Transcription Factor Network
- (2012) Laura A. Simmons Kovacs et al. MOLECULAR CELL
- Oncogenic NRAS signaling differentially regulates survival and proliferation in melanoma
- (2012) Lawrence N Kwong et al. NATURE MEDICINE
- The role of CCND1 alterations during the progression of cutaneous malignant melanoma
- (2012) Laura Vízkeleti et al. TUMOR BIOLOGY
- Phase I study of PD 0332991, a cyclin-dependent kinase inhibitor, administered in 3-week cycles (Schedule 2/1)
- (2011) G K Schwartz et al. BRITISH JOURNAL OF CANCER
- The meaning of p16ink4aexpression in tumors
- (2011) Agnieszka K. Witkiewicz et al. CELL CYCLE
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Melanoma survival in the United States, 1992 to 2005
- (2011) Lori A. Pollack et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
- (2011) Paul B. Chapman et al. NEW ENGLAND JOURNAL OF MEDICINE
- Driving the cell cycle with a minimal CDK control network
- (2010) Damien Coudreuse et al. NATURE
- Estrogen Regulation of Cyclin E2 Requires Cyclin D1 but Not c-Myc
- (2009) C. E. Caldon et al. MOLECULAR AND CELLULAR BIOLOGY
- Characterization of Coordinated Immediate Responses by p16INK4A and p53 Pathways in UVB-Irradiated Human Skin Cells
- (2008) Zakaria Y. Abd Elmageed et al. JOURNAL OF INVESTIGATIVE DERMATOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation